Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Lobo, Maria Luísa ^a   Esteves, Francisco ^a   de Sousa, Bruno ^b   Cardoso, Fernando ^a   Cushion, Melanie T ^c   Antunes, Francisco ^d   Matos, Olga ^a  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1,3 GLUCAN; CASPOFUNGIN; COTRIMOXAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FLUORESCENCE ANALYSIS; FUNGUS IDENTIFICATION; LOW DRUG DOSE; MALE; MICROSCOPY; MONOTHERAPY; MOUSE; NONHUMAN; PATHOGEN CLEARANCE; PILOT STUDY; PNEUMOCYSTIS; PNEUMOCYSTIS MURINA; PNEUMOCYSTIS PNEUMONIA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; ECHINOCANDINS; MALE; MICE; MICE, INBRED BALB C; PNEUMONIA, PNEUMOCYSTIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84881094365     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070619     Document Type: Article

References (34)

1. Espinel-Ingroff A, (2009) Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol 26: 15-22.
2. Enoch DA, Ludlam HA, Brown NM, (2006) Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 55: 809-18.
3. Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, et al. (2010) Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE 5: e8524.
4. Esteves F, Gaspar J, de Sousa B, Antunes F, Mansinho K, et al. (2012) Pneumocystis jirovecii multilocus genotyping in pooled DNA samples: a new approach for clinical and epidemiological studies. Clin Microbiol Infect 18: E177-E184.
5. Morris A, Sciurba FC, Norris KA, (2008) Pneumocystis: a novel pathogen in chronic obstructive pulmonary disease? COPD 5: 43-51.
6. Calderon EJ, Gutierrez-Rivero S, Durand-Joly I, Dei-Cas E, (2010) Pneumocystis infection in humans: diagnosis and treatment. Expert Rev Anti Infect Ther 8: 683-701.
7. Huang L, Cattamanchi A, Davis JL, den Boon S, Kovacs J, et al. (2011) HIV-associated Pneumocystis pneumonia. Proc Am Thorac Soc 8: 294-300.
8. Aliouat-Denis CM, Chabe M, Demanche C, Aliouat eM, Viscogliosi E, et al. (2008) Pneumocystis species, co-evolution and pathogenic power. Infect Genet Evol 8: 708-26.
9. Redhead SA, Cushion MT, Frenkel JK, Stringer JR, (2006) Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J Eukaryot Microbiol 53: 2-11.
10. Thomas CF Jr, Limper AH, (2007) Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 5: 298-308.
11. Stringer JR, (1996) Pneumocystis carinii: what is it, exactly? Clin Microbiol Rev 9: 489-98.
12. Powles MA, Liberator P, Anderson J, Karkhanis Y, Dropinski JF, et al. (1998) Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 42: 1985-9.
13. Schmatz DM, Romancheck MA, Pittarelli LA, Schwartz RE, Fromtling RA, et al. (1990) Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci U S A 87: 5950-4.
14. Barry SM, Johnson MA, (2001) Pneumocystis carinii pneumonia: a review of current issues in diagnosis and management. HIV Med 2: 123-32.
15. Matos O, Esteves F, (2010) Epidemiology and clinical relevance of Pneumocystis jirovecii Frenkel, 1976 dihydropteroate synthase gene mutations. Parasite 17: 219-32.
16. Letscher-Bru V, Herbrecht R, (2003) Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 51: 513-21.
17. Finkelman MA, (2010) Pneumocystis jirovecii infection: cell wall (1-3)-B-D-glucan biology and diagnostic utility. Crit Rev Microbiol 36: 271-81.
18. Vazquez JA, Sobel JD, (2006) Anidulafungin: a novel echinocandin. Clin Infect Dis 43: 215-22.
19. Matsumoto Y, Yamada M, Amagai T, (1991) Yeast glucan of Pneumocystis carinii cyst wall: an excellent target for chemotherapy. J Protozool 38: 6S-7S.
20. Utili R, Durante-Mangoni E, Basilico C, Mattei A, Ragone E, et al. (2007) Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe Pneumocystis pneumonia in solid organ transplant recipients. Transplantation 84: 685-8.
21. Annaloro C, Della VA, Usardi P, Lambertenghi DG, (2006) Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis 25: 52-4.
22. Beltz K, Kramm CM, Laws HJ, Schroten H, Wessalowski R, et al. (2006) Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia. Klin Padiatr 218: 177-9.
23. Walzer PD, Foy J, Steele P, Kim CK, White M, et al. (1992) Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 36: 1935-42.
24. Costa MC, Gaspar J, Mansinho K, Esteves F, Antunes F, et al. (2005) Detection of Pneumocystis jirovecii dihydropteroate synthase polymorphisms in patients with Pneumocystis pneumonia. Scand J Infect Dis 37: 766-71.
25. Esgalhado R, Esteves F, Antunes F, Matos O, (2013) Study of the epidemiology of Pneumocystis carinii f. sp. suis in abattoir swine in Portugal. Med Mycol 51(1): 66-71.
26. Ruan S, Tate C, Lee JJ, Ritter T, Kolls JK, et al. (2002) Local delivery of the viral interleukin-10 gene suppresses tissue inflammation in murine Pneumocystis carinii infection. Infect Immun 70: 6107-13.
27. Holten-Andersen W, Kolmos HJ, (1989) Comparison of methenamine silver nitrate and Giemsa stain for detection of Pneumocystis carinii in bronchoalveolar lavage specimens from HIV infected patients. APMIS 97: 745-7.
28. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, et al. (2008) Contribution of the (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 46: 1009-13.
29. Hufeldt MR, Nielsen DS, Vogensen FK, Midtvedt T, Hansen AK, (2010) Family relationship of female breeders reduce the systematic inter-individual variation in the gut microbiota of inbred laboratory mice. Lab Anim 44(4): 283-289.
30. Esteves F, Gaspar J, Marques T, Leite R, Antunes F, et al. (2010) Identification of relevant single-nucleotide polymorphisms in Pneumocystis jirovecii: relationship with clinical data. Clin Microbiol Infect 16: 878-84.
31. Limper AH, Lebron F, Evans SE, Hahn RY, (2003) Pneumocystis carinii: cell wall beta-glucan-mediated pulmonary inflammation. J Eukaryot Microbiol 50Suppl: 646.
32. Vassallo R, Standing JE, Limper AH, (2000) Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol 164: 3755-63.
33. Yoshida M, Roth RI, Grunfeld C, Feingold KR, Levin J, (1996) Soluble (1->3)-beta-D-glucan purified from Candida albicans: biologic effects and distribution in blood and organs in rabbits. J Lab Clin Med 128: 103-114.
34. Linke MJ, Ashbaugh A, Collins MS, Lynch K, Cushion MT, (2013) Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of Pneumocystis pneumonia. Infect Immu 81: 984-95.